Company intelligence / Profile preview

Ridgeline Discovery

Basel, Basel-City, Switzerland

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Ridgeline Discovery is not a traditional therapeutics company but rather a biotech venture creation engine. It builds and operates new biotech companies focused on novel therapeutic platforms, primarily in oncology and immunology. Its own internal pipeline includes preclinical-stage bispecific antibody programs targeting FGFR2 for intrahepatic cholangiocarcinoma. Several of its built companies have advanced to clinical development or commercialization independently.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculesBiologics (including bispecific antibodies)Gene/cell therapy
Industry: Biotech

Partnerships

Partnerships with entrepreneurs and leading academics across Europe, US and Rest of Worldclose ties to Versant Ventures-funded portfolio/created companies

Beyond the preview

Go deeper on Ridgeline Discovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ridgeline Discovery.

Explore the full profile